Lumateperone

Lumateperone (also known as ITI-007) is an antipsychotic medication developed by Intra-Cellular Therapies for the treatment of schizophrenia, bipolar disorder, and depression. It was approved by the FDA in December 2019 for the treatment of schizophrenia in adults.

Mechanism of Action

Lumateperone acts as a serotonin receptor antagonist, dopamine receptor phosphoprotein modulator, and glutamate receptor modulator. It has a unique mechanism of action that differs from other antipsychotic drugs.

Medical Uses

Lumateperone is used primarily for the treatment of schizophrenia in adults. It is also being investigated for potential use in treating bipolar disorder and depression.

Side Effects

Common side effects of lumateperone include somnolence, nausea, dry mouth, and weight gain. Serious side effects may include neuroleptic malignant syndrome, tardive dyskinesia, and orthostatic hypotension.

History

Lumateperone was developed by Intra-Cellular Therapies and received FDA approval in December 2019. It is marketed under the brand name Caplyta.

See Also

• List of antipsychotic drugs
• Schizophrenia
• Bipolar disorder
• Depression

References

Lumateperone Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski